An Israeli-developed drug to help obese people lose weight has shown positive signs of success in Phase II clinical trials being conducted in the US, reported the Globes business daily.
OBEcure Ltd. reported significant weight loss in women under the age of 50 who are participating in the trial of its OBE101 drug. The only group of women under the age of 50 that did not show positive results was women of Hispanic descent.
Earlier tests suggested that OBE101 was ineffective. But a decision to adjust dosages based on age, gender and ethnic background reaped benefits in the second round.
OBEcure, which is a subsidiary of Bio-Light Israeli Life Sciences Investments Ltd., plans to pursue additional clinical trials before going to market with OBE101.